The Sequels to Ozempic: What the Science Says About the Next Wave of Weight-Loss Drugs

Semaglutide, the active ingredient in Ozempic, is FDA approved for managing type 2 diabetes, chronic kidney disease and weight loss, and it is the last of those that turned the drug into a commercial phenomenon. According to a science explainer broadcast reviewing the research pipeline, that success has pulled dozens of drugs into the pipeline looking to capitalize on or improve the formula. The explainer poses the question directly: could the sequels be "new and improved or an unwelcome remake?"

The explainer adds a caveat worth carrying forward: it does not endorse weight loss for its own sake, and frames the decision as one for a patient and their doctor as part of overall health goals.

How the original works, and why that matters for the sequels

GLP-1 stands for glucagon-like peptide 1, a naturally occurring hormone, most of it made by cells in the intestines in response to a meal. It travels to the pancreas and binds GLP-1 receptors, which tell the pancreas to release insulin. Semaglutide is a GLP-1 receptor agonist, meaning it mimics that hormone closely enough that the receptor, as the report puts it, says "close enough" and proceeds with releasing insulin. Ozempic first earned FDA approval in 2017 for type 2 diabetes and related complications.

The weight-loss effect is a side door. GLP-1 receptors are not confined to the pancreas. In the gut, activated receptors slow stomach emptying so people feel full longer. In the brain, the report says researchers think semaglutide interacting with those receptors dampens hunger and reduces food cravings. Marketed for weight loss, the same molecule is sold as Wegovy at different dosing. Semaglutide is not the only GLP-1 receptor agonist on the market — the report notes a newer one approved as recently as April 2026, formulated as a pill rather than an injection. Understanding the mechanism explains the pipeline strategy: nearly every successor is an attempt to hit more hormone receptors at once, or to hit a different receptor entirely.

The multi-receptor drugs are posting the biggest numbers

Zepbound, active ingredient tirzepatide, already goes beyond GLP-1 by also mimicking GIP, a separate hormone that stimulates insulin release in response to meals and helps manage hunger cues in the brain. The report describes it as currently the only FDA-approved dual receptor agonist, though it notes many drug companies are looking to change that.

CagriSema pairs semaglutide with cagrilintide, which mimics amylin, another hormone that slows stomach emptying and promotes satiety. In trials the combination beat either component alone: patients on CagriSema dropped an average of 20 percent of body weight, against around 15 percent for semaglutide and around 11 percent for cagrilintide. A follow-up trial replicated the weight-loss result in patients with type 2 diabetes, and the drug showed significant reductions in hemoglobin A1C. The last of the phase 3 trials are estimated to end in late 2026 and the drug company has already applied for approval.

Amycretin folds the same two-pathway idea into a single peptide binding both GLP-1 and amylin receptors, with some patients dropping up to 24 percent of baseline body weight. It began phase 3 trials in 2026 for both obesity and type 2 diabetes, after a phase 2 trial in which almost 90 percent of patients reached acceptable A1C levels. The report judges it likely that some version of this semaglutide-amylin hybrid will be approved in the next few years.

The most aggressive is retatrutide, a triple agonist hitting GLP-1, GIP and glucagon receptors. Counterintuitively, glucagon raises blood sugar, but the report notes it also increases insulin secretion, decreases appetite and slows stomach emptying, with some researchers hypothesizing cross-reactivity with GLP-1 receptors. Crucially, retatrutide does not simply copy the natural hormones. It binds the GIP receptor far more strongly than the natural version while GLP-1 and glucagon get weaker binding — customizing how hard each receptor is stimulated, which the report stresses matters because stronger is not always better in pharmacology. At the highest phase 2 dose, participants averaged a 24 percent decrease in body weight after a year of use. The report says it will be several years before all phase 3 trials wrap up, but that some already-published results report almost 30 percent body weight losses. Retatrutide is also being investigated for reducing cardiovascular events and managing chronic kidney disease.

The safety picture is the real constraint

Nausea and other stomach upset are near-universal across this class, and the report says the only real way to deal with them so far has been starting with low doses and slowly increasing. More severe risks named include kidney damage, pancreatitis and thyroid cancer. A separate concern is body composition: a phase 2 trial combining semaglutide with bimagrumab, designed to steer loss toward fat while preserving muscle, produced large weight reductions and about 20 percent less muscle loss than semaglutide alone.

Outside the GLP-1 family, results are poor

Cannabinoid receptors are an obvious hunger target given the well-known appetite effects of cannabis, but progress has been slow, partly because interfering with reward pathways is fraught. Only one such drug, monlunabant, has completed two phase 2 trials, and the results were discouraging: at the highest dosage over 90 percent of participants saw adverse effects including psychiatric ones, and over 40 percent withdrew. The report adds an important caveat that cuts against overreading this — a "weirdly high" number of placebo-group participants also reported adverse side effects. Neuropeptide Y2 receptor agonists are similarly early and troubled. A phase 1 trial combining one with a GLP-1 to ease GI problems found additive weight-loss effects but the GI issues persisted, and a mouse study found the drug could enhance a dual glucagon/GLP-1 agonist without inducing significant weight loss on its own.

What this signals, and what remains unconfirmed

The pattern in the report is that the drugs posting the largest losses are all variations on the same GLP-1 and glucagon-like pathways — stacking and tuning known hormone targets rather than opening new biology. The alternatives the report surveys are markedly further behind: the cannabinoid approach has cleared two phase 2 trials but with tolerability problems the report says put it "a ways off," and the neuropeptide Y2 work is still at phase 1 and mouse studies.

Several figures carry real uncertainty. Retatrutide's near-30 percent figure comes from partial published results with phase 3 trials still years from completion, and the report does not specify which trial phase those results are drawn from; its 24 percent figure is a highest-dose phase 2 average, not a general expectation. CagriSema and amycretin both remain unapproved, with phase 3 data still landing. All of the above rests on a single science explainer summarizing the literature, not on direct review of the underlying trial publications.